Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Médioni, Jacques ^a   Di Palma, Mario ^b   Guillot, Aline ^c   Spaeth, Dominique ^d   Théodore, Christine ^e  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Lucien Neuwirth Cancer Institute   (France)

^d Centre d'Oncologie de Gentilly   (France)

^e FOCH HOSPITAL   (France)

Author keywords

Chemotherapy; CURVE (urothelial carcinoma patients treated by VinfluninE study in French); Metastatic; Platinum pre treated; Routine; Urothelial carcinoma; Vinflunine

Indexed keywords

HEMOGLOBIN; VINFLUNINE; PLATINUM; VINBLASTINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CAUSE OF DEATH; CONSTIPATION; CREATININE CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; LEUKOPENIA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC UROTHELIAL CARCINOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OCCLUSION; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; SUBOCCLUSIVE SYNDROME; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; VOMITING; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; CARCINOMA; CLASSIFICATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; UROLOGIC NEOPLASMS; UROTHELIUM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PLATINUM; RETROSPECTIVE STUDIES; UROLOGIC NEOPLASMS; UROTHELIUM; VINBLASTINE;

EID: 84978858663     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2262-9     Document Type: Article

References (25)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on day/month/year.
2. French National Cancer Institute (Institut National du Cancer) Epidemiology of cancer in France - Incidence and mortality. http://www.ecancer.fr/content/download/142167/1769928/file/Les%20cancers%20en%20france%20-%20Edition%202015%20-%20Faits%20et%20chiffres.pdf
3. Prasad SM, Decastro GJ, Steinberg GD. Urothelial carcinoma of the bladder: definition, treatment and future efforts. Nat Rev Urol. 2011;8:631-42. doi: 10.1038/nrurol.2011.144Review.
4. Sverrisson FE, Espiritu PN, Spiess P. New therapeutic targets in the management of urothelial carcinoma of the bladder. Res Rep Urol. 2013;5:53-65. 10.2147/RRU.S29131.
5. Nadal R, Bellmunt J. New treatments for bladder cancer: when will we make progress? Curr Treat Options Oncol. 2014;15(1):99-114.
6. Bellmunt J, Orsola A, Wiegel T, Guix M, De Santis M, Kataja V, et al. Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22 Suppl 6:vi45-9.
7. Stenzl A, Witjes JA, Compérat E, Cowan N.C, De Santis M, Gakis G, Lebret T, Ribal M J, Sherif A. EAU Guidelines on Bladder Cancer Muscle-invasive and Metastatic. European Association of Urology 2012 update. www.uroweb.org.
8. Ngan VK, Bellman K, Panda D, Hill BT, Jordan MA, Wilson L. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res. 2000;18:5045-51.
9. Gerullis H. Vinflunine: a fluorinated vinca alkaloid for bladder cancer therapy. Drugs of Today. 2011;47:17-25.
10. Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S, von der Maase H. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454-61.
11. Culine S, Theodore C, De Santis M, Bui B, Demkow T, Lorenz J, Rolland F, Delgado FM, Longerey B, James N. A Phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer. 2006;94:1395-401.
12. Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, Sternberg CN, Smith DC, Ringuette S, de Wit E, Pautret V, George C. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large Phase 2 study. Cancer. 2009;115:4110-7.
13. CHMP Assessment Report for JAVLOR® - International non-proprietary name Javlor® European Public Assessment Report doc EMEA/CHMP/370293/2009.
14. Witjes J A, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Sherif A. Guidelines on Muscle-invasive and Metastatic Bladder Cancer update March 2013.
15. Soulié M, Coloby P, Irani JT, Lebret JJ, Patard C, Pfister P, Richaud J, Rigaud L, Salomon, and Members of CCAFU. CCAFU Recommendations 2013: Diagnosis, treatment, follow-up of urological cancers. Prog Urol. 2010;20 Suppl 4:S211-4.
16. Pfister C, Roupret M, Neuzillet Y, Larré S, Pignot G, Quintens H, Houedé N, Compérat E, Colin P, Roy C., Davin J L, Guy L, Irani J, Lebret T, Coloby P, Soulié M, and Members of CCAFU. Recommendations 2013: Bladder carcinoma. Prog Urol. 2013;23 Suppl 2:S105-25.
17. Bellmunt J, Choueiri TK, Fougeray R, Schutz FAB, Salhi Y, Winquist E, Culine S, von der Maase H, Vaughn D J, Rosenberg, J E. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28:1850-5.
18. Common Terminology Criteria for Adverse Events (CTCAE) v3.0 (Publish Date August 9, 2006) http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
19. Hegele A, de Geeter P, Goebell P, Matz U, de Schultz W, Retz M. Vinflunine in routine practice for the treatment of advanced or metastatic urothelial cell carcinoma in Germany. Eur J Cancer. 2013;49(Suppl2):S669.
20. Chirivella I, Grande E, Lopez-Criado P, González GB, Fernández O, Santander C. Vinflunine as a second-line chemotherapy for patients with transitional cell carcinoma of the urothelium: a multicentre retrospective study. Eur J Cancer. 2013;49 Suppl 2:S671.
21. Bellmunt J, Fougeray R, Rosenberg JE, von der Maase H, Schutz FA, Salhi Y, et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol. 2013;24:1466-72.
22. Yafi FA, North S, Kassouf W. First- and second-line therapy for metastatic urothelial carcinoma of the bladder. Curr Oncol. 2011;18:e25-34.
23. De Santis M, Wiechno P, Lucas C, Su WC, Albige SL, Lin CC, Vaissière N, Burillon J.P, Culine S. Preliminary data on feasibility of vinflunine (VFL)-based combinations as 1st line in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC): VFL/gemcitabine vs. VFL/CBDCA in a randomised international phase II trial (JASINT1). Eur J Cancer. 2013;49(Suppl2):S642.
24. Castellano D, Puente J, de Valasco G, Chirivella I, López-Criado P, Mohedano N, et al. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer. 2014;14:779.
25. Retz M, de Geeter P, Goebell PJ, Ullrich Matz U, de Schultz W, Hegele A. Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience. BMC Cancer. 2015;15:455. doi: 10.1186/s12885-015-1434-3.